Laparoscopic rectal surgery for middle and lower rectal cancer

Fukunaga, Yosuke; Higashino, Masayuki; Tanimura, Sinya; Takemura, Masashi; Fujiwara, Yushi

doi:10.1007/s00464-009-0551-y

Cited by 18 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with previous studies our data suggests that laparoscopic rectal resection provides similar oncological long-term outcomes compared to open rectal resection (DFS 52.1%–81%, OS 52,9%–75,3) [17, 21–25]. The oncological safety issues of laparoscopic approach, in terms of number of harvested lymph nodes, recurrence rate, and cancer-related survival, are all in line with those reported in Abraham's meta-analysis in 2004 [21].…”

Section: Discussionsupporting

confidence: 92%

A Single Centre Retrospective Evaluation of Laparoscopic Rectal Resection with TME for Rectal Cancer: 5-Year Cancer-Specific Survival

Quarati

Summa

Priora

et al. 2011

International Journal of Surgical Oncology

View full text Add to dashboard Cite

Laparoscopic colon resection has established its role as a minimally invasive approach to colorectal diseases. Better long-term survival rate is suggested to be achievable with this approach in colon cancer patients, whereas some doubts were raised about its safety in rectal cancer. Here we report on our single centre experience of rectal laparoscopic resections for cancer focusing on short- and long-term oncological outcomes. In the last 13 years, 248 patients underwent minimally invasive approach for rectal cancer at our centre. We focused on 99 stage I, II, and III patients with a minimum follow-up period of 5 years. Of them 43 had a middle and 56 lower rectal tumor. Laparoscopic anterior rectal resection was performed in 71 patients whereas laparoscopic abdomino-perineal resection in 28. The overall mortality rate was 1%; the overall morbidity rate was 29%. The 5-year disease-free survival rate was 69.7%, The 5-year overall survival rate was 78.8%.

show abstract

Section: Discussionsupporting

confidence: 92%

A Single Centre Retrospective Evaluation of Laparoscopic Rectal Resection with TME for Rectal Cancer: 5-Year Cancer-Specific Survival

Quarati

Summa

Priora

et al. 2011

International Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Surgical treatment without radiotherapy in Japan has shown results that are no worse than those in Western countries using chemoradiotherapy (CRT) with surgery, and extrapolating the results of preoperative treatment in Western countries to Japan would be controversial. The Japanese Classification of Colorectal Carcinoma (6) describes that the standard treatment is surgery without radiotherapy, based on several reports, which demonstrated a low 5-year local recurrence rate of 3.0-6.9% (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial

Ito

Akagi

Etoh

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Treatment results of locally advanced rectal cancer without preoperative chemoradiotherapy (CRT) in Japan do not differ from those of Western countries. Preoperative CRT with new anticancer agents may decrease local recurrence rate and prevent distant metastases, thus improving survival. We conducted a trial to evaluate feasibility of neoadjuvant CRT using S-1 in patients with locally advanced rectal cancer. A multi-institutional (17 specialized centres), interventional, phase II trial was conducted from April 2009 to August 2011. Patients fulfilling the following requirements before neoadjuvant CRT were included: histologically proven rectal carcinoma; tumour in the upper or lower rectum; cancer classified as T3-4 N0-3 M0. Neoadjuvant CRT with S-1 (80 mg/m/day on days 1-5, 8-12, 22-26, and 29-33) and irradiation (total 45 Gy/25 fr, 1.8 Gy/day, on days 1-5, 8-12, 15-19, 22-26, and 29-33) was performed. Total mesorectal excision with D3 lymphadenectomy was performed during weeks 4 and 8 after completion of neoadjuvant CRT. The primary endpoint was completion rate of neoadjuvant CRT. Secondary endpoints were response rate to neoadjuvant CRT, short-term clinical outcomes, curative resection rate, and pathologic response (grade 2/3). Of the 37 patients included, 86.5% completed neoadjuvant CRT (95% CI, 75.5-97.5%), and 10.8% (4) experienced an adverse event (grade 3/4). Response rate (RECIST 1.0) was 56.8% (95% CI, 40.8-72.7%), and pathologic response rate was 48.6% (95% CI, 32.5-64.8%). This study demonstrated that neoadjuvant-synchronous S-1+radiotherapy for locally advanced rectal cancer was feasible in terms of pathologic response and adverse events. Registration number: UMIN-CTR, No. C003396.

show abstract

“…The laparoscopic surgery technique for radical resection is a five-port technique as described by Yosuke Fukunaga et al [13]. Under general and epidural anesthesia, the patient is placed in lithotomy position and tilted to the right.…”

Section: Surgical Techniquementioning

confidence: 99%

Laparoscopic surgery after endoscopic resection for rectal cancer and neuroendocrine tumors

et al. 2014

View full text Add to dashboard Cite

show abstract

Laparoscopic rectal surgery for middle and lower rectal cancer

Abstract: Laparoscopic low anterior resection achieves acceptable short- and long-term outcomes. It is a useful option even for advanced lower rectal cancer.

Cited by 18 publications

References 20 publications

A Single Centre Retrospective Evaluation of Laparoscopic Rectal Resection with TME for Rectal Cancer: 5-Year Cancer-Specific Survival

A Single Centre Retrospective Evaluation of Laparoscopic Rectal Resection with TME for Rectal Cancer: 5-Year Cancer-Specific Survival

A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial

Laparoscopic surgery after endoscopic resection for rectal cancer and neuroendocrine tumors

Contact Info

Product

Resources

About